Danaher Corporation vs Quantumscape Corp — how do they compare? Danaher Corporation trades at $220.03 (market cap $152.87B), while Quantumscape Corp trades at $4.6 (market cap $2.82B). The key difference: Danaher Corporation is far larger — about 54.2× Quantumscape Corp's market cap, and Danaher Corporation pays a 0.74% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Quantumscape Corp for 37 Days on average.
| DHR | QS | |
|---|---|---|
Market Cap | $152.87B | $2.82B |
Volume | 5,228,698 | 21,878,246 |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $18.44 |
52-Week Low | $161.91 | $4.52 |
Typical Hold Time | 69 Days | 37 Days |
Enterprise Value | $175.08B | $2.03B |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
QuantumScape (QS) trades at $4.545, up 0.55% on the day, but remains in a bearish technical trend with significant fundamental challenges. The company continues to operate without revenue while reporting substantial losses (-$435.05M net income in 2025). Recent earnings show mixed results with two beats and one miss in the last four quarters. The stock faces headwinds from delayed commercialization timelines and insider selling activity, though institutional interest persists with Bank of New York Mellon establishing a new position.
QS represents a high-risk, speculative investment opportunity in solid-state battery technology. The primary opportunity lies in potential commercialization success with automotive partners like Volkswagen, while major risks include continued cash burn, competitive threats, and execution delays. Analyst consensus remains cautious with 73% hold ratings and a $10.35 price target suggesting 128% upside from current levels, but the path to profitability remains uncertain.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →